Now that the Abbott Freestyle Libre has received FDA clearance, Abbott and Dexcom will be forced into tight competition in the US market. On Dexcom’s third quarter call, CEO Kevin Sayer spent some ...
Abbott (NYSE:ABT) today unveiled a new feature within its FreeStyle Libre app for continuous glucose monitoring (CGM).
These two companies are battling for market share of continuous glucose monitoring devices for diabetes, with each coming out with new models soon. There are 34 million diabetics in the United States, ...
With multiple COVID-19 vaccines being distributed across the world, companies focused on other medical conditions are now grabbing the Street's attention. One such disorder is diabetes, which is ...
Please confirm that you would like to log out of Medscape. If you log out, you will be required to enter your username and password the next time you visit. Log out ...
Abbott Laboratories (NYSE: ABT) and DexCom (NASDAQ: DXCM) turned in stellar performances in 2018. Abbott's shares jumped 27%, while DexCom stock more than doubled. It's a different story so far this ...
With multiple COVID-19 vaccines being distributed across the world, companies focused on other medical conditions are now grabbing the Street's attention. One such disorder is diabetes, which is ...
Two companies are making life a lot easier for people with diabetes. Abbott Laboratories (ABT 1.18%) and DexCom (DXCM +0.97%) market devices that allow for convenient monitoring of blood sugar levels ...
Two companies are making life a lot easier for people with diabetes. Abbott Laboratories (NYSE: ABT) and DexCom (NASDAQ: DXCM) market devices that allow for convenient monitoring of blood sugar levels ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback